Preliminary evidence of effects of potassium chloride on a metabolomic path to diabetes and cardiovascular disease.

Published online

Journal Article

INTRODUCTION: Low potassium intake can affect cardiovascular disease (CVD) risk and cardiometabolic risk factors. OBJECTIVE: We hypothesize that potassium chloride (KCl) supplementation can improve cardiovascular risk metabolomic profile. METHODS: In this secondary analysis of a pilot randomized clinical trial (RCT) of 26 participants with prediabetes randomized to KCl or placebo, we performed targeted mass-spectrometry-based metabolomic profiling on baseline and 12-week (end-of-study) plasma samples. Principal component analysis (PCA) was used to reduce the many correlated metabolites into fewer, independent factors that retain most of the information in the original data. RESULTS: Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11). CONCLUSIONS: KCl supplementation may improve circulating BCAA levels, which may reflect improvements in overall cardiometabolic risk profile. CLINICAL TRIALS REGISTRY: Clinicaltrials.gov identifier: NCT02236598; https://clinicaltrials.gov/ct2/show/NCT02236598.

Full Text

Duke Authors

Cited Authors

  • Chatterjee, R; Davenport, CA; Kwee, L; D'Alessio, D; Svetkey, LP; Lin, P-H; Slentz, CA; Ilkayeva, O; Johnson, J; Edelman, D; Shah, SH

Published Date

  • June 18, 2020

Published In

Volume / Issue

  • 16 / 7

Start / End Page

  • 75 -

PubMed ID

  • 32556595

Pubmed Central ID

  • 32556595

Electronic International Standard Serial Number (EISSN)

  • 1573-3890

Digital Object Identifier (DOI)

  • 10.1007/s11306-020-01696-w

Language

  • eng

Conference Location

  • United States